With RAS-targeted therapies gaining ground in pancreatic cancer, Incyte is advancing its own contender. On Monday, the company shared what it called "encouraging" early data for its experimental KRAS G12D inhibitor INCB161734, along with two new partnerships, including one with Bristol Myers Squibb, to test the drug in separate combos against the disease. Phase I findings, presented at the European Society for Medical Oncology (ESMO) congress, showed the oral drug produced an objective response

Divarasib monotherapy demonstrated superior efficacy over first-generation KRAS G12C inhibitors, lowering the risk of disease progression or death by 42% and the overall risk of death by 44%, in the phase III Krascendo 1 study1,2 At the time of primary analysis, divarasib achieved a median overall survival of approximately 18 months, compared to 12 months for sotorasib or adagrasib1,2 No new safety signals were observed with divarasib; the most common treatment-related adverse events were mainly

Pfizer scored a green light from the FDA on Monday to move its prostate cancer combination up earlier in the treatment paradigm. The US regulator approved PARP inhibitor Talzenna (talazoparib) plus androgen receptor pathway inhibitor Xtandi (enzalutamide) for patients with homologous recombination repair (HRR) gene-mutated metastatic hormone-sensitive prostate cancer (mHSPC), also known as androgen pathway modulation-naïve or -sensitive disease. The regulatory nod expands the regimen's label, i

Oct. 26, 2026 -- Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high quality medicines for the treatment of cancer, metabolic, autoimmune and other major diseases, today announced that a New Indication Application for sintilimab in combination with Nolgileucel injection (GC101) has been accepted for review by the China National Medical Products Administration (NMPA). The application is proposed to be sin

Pathos AI and its Foundry platform are hitting their stride. The drug developer clinched $237 million in fresh funding on Friday while also inking a partnership with Bristol Myers Squibb and Tempus AI that will leverage Foundry's agentic AI capabilities to design better clinical trials for neurological diseases. BMS was the lead investor on Pathos' series E, which it raised at a valuation of about $3 billion — nearly double its valuation when it secured a $365-million series D last May. The fund

Median DOR of 44.3 months supports durability of response 4-year overall survival rate of 35.3% and median OS of 28.2 months suggest meaningful long-term survival Long-term survival of 42+ - 60+ months observed among complete responders Oct. 23, 2026 -- Rakuten Medical, Inc., a global biotechnology company developing and commercializing Alluminox® platform-based photoimmunotherapy, today announced the presentation of long-term follow-up results from the Phase 1b/2 ASP-1929-181 study (NCT0430579

Faster and higher expansion of tumor-targeting CD8 T cells associated with longer overall survival in previously treated mismatch repair proficient (pMMR) metastatic colorectal cancer EO4010 was well tolerated and expanded tumor-targeting CD8 T cells in most patients, with expansion detectable after two to three administrations Association between CD8 T-cell expansion and clinical outcome, previously reported for EO2463 in lymphoma, now also observed with EO4010 in a solid tumor Data to be prese

Funding follows rapid portfolio expansion and will power the initiation of a registrational study for AI-identified asset JSKN-016 October 23, 2026 — Pathos AI, Inc., a clinical-stage AI and technology company advancing its own therapeutic pipeline of drugs, today announced the closing of a $237 million Series E financing round at a post-money valuation of approximately $3 billion. The financing was led by Bristol Myers Squibb (NYSE: BMY), alongside participation from existing investors. The c

South Korean biopharmaceutical company Celltrion has acquired exclusive global development and commercialisation rights to Kaigene’s investigational monoclonal antibody, KG013, in a deal worth up to Won769bn ($580m). The financial package includes an upfront payment alongside milestone payments tied to specific development, regulatory, and commercial targets. Royalties on net sales remain separate from the package. Kaigene also retains an option to co-market the candidate in South Korea under th

BioInvent International (STO:BINV) - Updated efficacy data in 34 evaluable patients with a chemotherapy-free regimen; randomized Part C will add BI-1808 to the new standard of care 24% objective response rate (8 of 34 evaluable patients: 1 complete and 7 partial responses), including patients with high-grade serous and clear cell carcinoma53% disease control rate, with several patients in stable disease beyond 10 months; 6 patients were still on treatment at data cutoffMedian progression-free su